Berlin Cures Expands Research Capabilities and Scientific Expertise with New Advisory Board
Accesswire
*BERLIN, GERMANY / ACCESSWIRE / April 3, 2024 / *Berlin Cures, a biotechnology company in Phase II clinical trial for a treatment..
*BERLIN, GERMANY / ACCESSWIRE / April 3, 2024 / *Berlin Cures, a biotechnology company in Phase II clinical trial for a treatment..
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity..
On every step of our journey - from being wild to civil - we had people who freely spoke about the ills in society. It's..